Otros idiomas Palatin Technologies, Inc.

Acciones

PTN

US6960775020

Mercado cerrado - Nyse Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
1,86 ^USD	+3,91 %		+6,29 %	-53,27 %

08/04	Palatin Anuncia los Resultados de los Datos Clínicos de la Fase 3 Pl9643 Melody-1 para la Enfermedad del Ojo Seco (Ded) Presentados en la Sociedad Americana de Catarata y Cirugía Refractiva (Ascrs) 2024	CI
28/02	Actualización del sector: Los valores del sector sanitario retroceden a última hora de la tarde	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Palatin to Host Virtual KOL Event 'Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance' on May 8, 2024	13:29
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	09/04
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	08/04
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	29/02
Sector Update: Health Care Stocks Decline Late Afternoon	28/02
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	28/02
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	06/02
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	05/02
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING	31/01
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024	09/01
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	08/01
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.	03/01
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million.	20/12
Top Premarket Decliners	15/12
PALATIN REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	15/11
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
PALATIN TO REPORT FIRST QUARTER FISCAL YEAR 2024 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON NOVEMBER 14, 2023	10/11
PALATIN ANNOUNCES CLOSING OF $5 MILLION REGISTERED DIRECT OFFERING	25/10/23
Palatin Technologies, Inc. announced that it has received $5.000001 million in funding	24/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Palatin Technologies, Inc.

Acciones

PTN

US6960775020

Otros idiomas

Filtros